| UHC Commercial Medical & Drug | Simponi Aria® (Golimumab) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| UHC Commercial Medical & Drug | Tocilizumab (Actemra®, Tofidence®, & Tyenne®) Injection for Intravenous Infusion – Commercial Medical Benefit Drug Policy | 2026-03-01 |
| Medical Mutual | Lymphir™ (denileukin diftitox-cxdl) (Intravenous) (EOV) | 2026-03-01 |
| Medical Mutual | Poteligeo® (mogamulizumab-kpkc) (Intravenous) (EOV) | 2026-03-01 |
| Medical Mutual | Provenge® (sipuleucel-T) (Intravenous) (EOV) | 2026-03-01 |
| Medical Mutual | Vyxeos® (daunorubicin and cytarabine – liposome) (Intravenous) (EOV) | 2026-03-01 |
| Paramount Healthcare | Molecular Diagnostic and Genetic Testing/
Genetic Counseling | 2026-03-01 |
| Paramount Healthcare | Gradient Compression Garments/Stockings | 2026-03-01 |
| Paramount Healthcare | Infertility and Reproductive Services | 2026-03-01 |
| Paramount Healthcare | Ocular Photoscreening | 2026-03-01 |